Quarterly report pursuant to Section 13 or 15(d)

Acquisition of Pelican Therapeutics - Narrative (Details)

v3.20.1
Acquisition of Pelican Therapeutics - Narrative (Details) - USD ($)
1 Months Ended 3 Months Ended
Jun. 30, 2016
May 31, 2016
Mar. 31, 2020
Mar. 31, 2019
Mar. 31, 2018
Dec. 31, 2019
Oct. 31, 2018
Sep. 30, 2018
Dec. 31, 2017
Business Acquisition [Line Items]                  
Discount rate     10.22%            
Accrued liabilities     $ 1,092,235     $ 1,676,467      
Goodwill     1,452,338     $ 1,452,338      
Revenue     901,880 $ 701,062          
Net loss (income)     (6,292,106) (5,715,476)          
Net loss     $ 6,373,420 $ 5,819,081          
Pelican Therapeutics, Inc.                  
Business Acquisition [Line Items]                  
Ownership interest in subsidiary     85.00%            
Pelican Therapeutics, Inc.                  
Business Acquisition [Line Items]                  
Percentage of voting interests acquired in acquisition             85.00% 80.00% 80.00%
Discount rate         10.22%        
Cash consideration         $ 200,000        
Goodwill                 $ 2,200,000
Percentage of non-controlling interest acquired     20.00%            
Amount awarded from CPRIT grant $ 15,200,000 $ 15,200,000              
Pelican Therapeutics, Inc. | Stockholders                  
Business Acquisition [Line Items]                  
Cash consideration         $ 300,000        
Pelican Therapeutics, Inc. | CEO, Two Directors and Affiliated Companies                  
Business Acquisition [Line Items]                  
Percentage of milestone payments that will be paid to related parties         51.00%